- Home
- BIOX vs CNTX Comparison
BIOX vs CNTX Comparison
Compare BIOX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOX
- CNTX
- Stock Information
- Founded
- BIOX 2001
- CNTX 2015
- Country
- BIOX Argentina
- CNTX United States
- Employees
- BIOX N/A
- CNTX N/A
- Industry
- BIOX Agricultural Chemicals
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- BIOX Industrials
- CNTX Health Care
- Exchange
- BIOX Nasdaq
- CNTX Nasdaq
- Market Cap
- BIOX 85.0M
- CNTX 75.6M
- IPO Year
- BIOX N/A
- CNTX 2021
- Fundamental
- Price
- BIOX $1.87
- CNTX $1.26
- Analyst Decision
- BIOX Buy
- CNTX Strong Buy
- Analyst Count
- BIOX 3
- CNTX 7
- Target Price
- BIOX $4.50
- CNTX $5.20
- AVG Volume (30 Days)
- BIOX 1.4M
- CNTX 500.2K
- Earning Date
- BIOX 11-10-2025
- CNTX 11-10-2025
- Dividend Yield
- BIOX N/A
- CNTX N/A
- EPS Growth
- BIOX N/A
- CNTX N/A
- EPS
- BIOX N/A
- CNTX N/A
- Revenue
- BIOX $333,300,000.00
- CNTX N/A
- Revenue This Year
- BIOX $6.77
- CNTX N/A
- Revenue Next Year
- BIOX $21.39
- CNTX N/A
- P/E Ratio
- BIOX N/A
- CNTX N/A
- Revenue Growth
- BIOX N/A
- CNTX N/A
- 52 Week Low
- BIOX $1.20
- CNTX $0.49
- 52 Week High
- BIOX $7.44
- CNTX $2.46
- Technical
- Relative Strength Index (RSI)
- BIOX 53.89
- CNTX 56.22
- Support Level
- BIOX $1.58
- CNTX $1.19
- Resistance Level
- BIOX $2.14
- CNTX $1.50
- Average True Range (ATR)
- BIOX 0.25
- CNTX 0.15
- MACD
- BIOX 0.09
- CNTX -0.02
- Stochastic Oscillator
- BIOX 71.99
- CNTX 39.78
About BIOX Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.